Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Orphazyme A/S
  6. News
  7. Summary
    ORPHA   DK0060910917


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Orphazyme A/S : Final Deadline for Investors with Losses Exceeding $500K to Actively Participate in the Orphazyme A/S (ORPH) Class Action - Bronstein, Gewirtz & Grossman, LLC

09/06/2021 | 10:01am EDT

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired (1) Orphazyme American depositary shares ("ADSs") pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about September 29, 2020 (the "IPO" or "Offering"); and/or (2) Orphazyme securities between September 29, 2020 and June 18, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/orph.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933 and the Securities Exchange Act of 1934.

The complaint alleges that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies, and specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (1) arimoclomol was not as effective in treating IBM as Defendants had represented; (2) arimoclomol was not as effective in treating ALS as Defendants had represented; (3) the arimoclomol NDA for NPC was incomplete and/or required additional evidence and data to support the benefit-risk assessment of that NDA; (4) as a result of (5), the FDA was unlikely to approve the arimoclomol NDA for NPC in its present form; (6) the Company's overall business prospects, as well as arimoclomol's commercial prospects, were significantly overstated; and (7) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/orph or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Orphazyme you have until September 7, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

ę Business Wire 2021
All news about ORPHAZYME A/S
10/14European ADRs Climb Higher in Thursday Trading
10/08European ADRs Move Higher in Friday Trading
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021 (Form 6-K)
10/07ORPHAZYME A/S : Modified long-term share-based incentive program for 2021
10/05ORPHAZYME A/S : provides regulatory and financial updates (Form 6-K)
10/05ORPHAZYME A/S : Says European Review of Arimoclomol Underway; Raises 2021 Cash Position Ou..
10/05ORPHAZYME A/S : provides regulatory and financial updates
09/23European ADRs Move Sharply Higher in Thursday Trading
09/16European ADRs Move Lower in Thursday Trading
09/15European ADRs Modestly Higher Wednesday as Energy Stocks Rally
More news
Analyst Recommendations on ORPHAZYME A/S
More recommendations
Sales 2021 24,4 M 3,80 M 3,80 M
Net income 2021 -634 M -98,9 M -98,9 M
Net cash 2021 122 M 19,0 M 19,0 M
P/E ratio 2021 -1,83x
Yield 2021 -
Capitalization 984 M 153 M 154 M
EV / Sales 2021 35,4x
EV / Sales 2022 30,7x
Nbr of Employees 180
Free-Float 98,6%
Duration : Period :
Orphazyme A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORPHAZYME A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 2
Last Close Price 28,16 DKK
Average target price 60,50 DKK
Spread / Average Target 115%
EPS Revisions
Managers and Directors
Christophe Bourdon Chief Executive Officer
Anders Fink Vadsholt Chief Financial Officer
Georges Gemayel Chairman
Thomas Kirkegaard Jensen Chief Scientific Officer
Claus BornŠs Senior Manager-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ORPHAZYME A/S-58.03%153
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820